

ASX ANNOUNCEMENT

4 November 2014

Date of Final EMA Committee Assessment Determined

Biomedical company, Tissue Therapies Limited (**ASX: TIS**) has been advised that the EMA Review Committee has deferred the submission of the Company's response to the 180-day questions until early 2015. This is the result of the EMA Review Committee's desire to manage its workload over the Christmas - New Year period.

Tissue Therapies was on track to meet the previously advised timetable (please see **ASX: TIS** EMA 180-Day Review Questions Received, 30 September 2014).

Based on this altered schedule from the EMA Review Committee, Tissue Therapies management has negotiated a firm submission date for the Company to provide its response to the Notified Body (BSI) and the commitment of BSI management to lodge the response with the EMA Review Committee on the new acceptance date of 26 January 2015, as has been confirmed by the EMA.

This provides certainty of dates from both BSI and the EMA for the last stage of the review of VitroGro® ECM:

Submission of response by Tissue Therapies to BSI	19 Jan 2015
Completion of BSI review and submission of response by BSI to the EMA Review Committee	26 Jan 2015
Review clock restart for final 30 calendar days	26 Jan 2015
EMA Review Committee assessment	26 Feb 2015

The results of an EMA Review Committee assessment are usually conveyed by the EMA to the Notified Body within a few working days. Tissue Therapies will then be advised of the result by BSI.

The Managing Director, Dr Steven Mercer commented, "This situation is frustrating but the Company now would appear to have certainty as to the timing for the last stage of the review for the approval of VitroGro® ECM for sale in the UK and Europe."

What is VitroGro® ECM

- VitroGro® ECM is a topically applied, biomimetic scaffold, comprising a synthetic extracellular matrix (ECM) protein.
- How it works: VitroGro® ECM replaces the degraded matrix of a hard to heal wound. VitroGro® ECM binds to a prepared wound bed and provides a physical structure (a scaffold) for cell attachment, which is a primary requirement for subsequent cell functions critical for healing, such as cell proliferation and migration ^[1].
- An optimal scaffold: One of the characteristics of hard to heal wounds is prolonged inflammation, which damages the native ECM that would normally guide the wound healing process ^[1,2,3,4]. Replacement of this damaged ECM is a beneficial strategy for treating hard to heal wounds ^[1]. VitroGro® ECM is ideal as an ECM replacement since its structural and functional elements mimic those present in the ECM at the early stages of normal wound healing.
- Expert health economics modelling indicates that VitroGro® ECM offers the opportunity for substantially more cost effective treatment of wounds compared to the current standard of care.

[1] Widgerow AD. Deconstructing the stalled wound. Wounds 2012

[2] Schultz GS. Extracellular Matrix: review of its roles in acute and chronic wounds. World Wide Wounds. 2005

[3] Moor AN. et al. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Rep Reg. 2009

[4] International consensus, Acellular matrices for treatment of wounds. Wounds Int. 2010

About Tissue Therapies Limited

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro® ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: www.tissuetherapies.com